--- title: "Seaport Therapeutics (NASDAQ:SPTX) Sets New 52-Week High - Time to Buy?" type: "News" locale: "en" url: "https://longbridge.com/en/news/295162148.md" description: "Seaport Therapeutics (NASDAQ:SPTX) reached a new 52-week high of $23.34, closing at $23.09 with significant trading volume. Analysts have issued mixed ratings, including 'Buy' and 'Hold', with an average price target of $38.40. The company recently reported quarterly earnings that missed consensus estimates. Additionally, Director Robert J. Hombach purchased 13,000 shares, signaling insider confidence." datetime: "2026-08-07T01:00:30.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295162148.md) - [en](https://longbridge.com/en/news/295162148.md) - [zh-HK](https://longbridge.com/zh-HK/news/295162148.md) generator: "portal-rs" --- # Seaport Therapeutics (NASDAQ:SPTX) Sets New 52-Week High - Time to Buy? Seaport Therapeutics, Inc. (NASDAQ:SPTX - Get Free Report)'s stock price reached a new 52-week high on Thursday . The company traded as high as $23.34 and last traded at $23.09, with a volume of 106561 shares. The stock had previously closed at $22.34. Get **Seaport Therapeutics** alerts: ## Analysts Set New Price Targets SPTX has been the topic of several recent research reports. Wolfe Research started coverage on shares of Seaport Therapeutics in a report on Tuesday, July 7th. They issued a "hold" rating on the stock. Zacks Research upgraded Seaport Therapeutics to a "hold" rating in a research note on Wednesday, May 27th. Stifel Nicolaus started coverage on Seaport Therapeutics in a research report on Tuesday, May 26th. They set a "buy" rating and a $30.00 price target for the company. HC Wainwright reissued a "buy" rating and issued a $50.00 price target on shares of Seaport Therapeutics in a report on Tuesday. Finally, Seaport Research Partners set a $50.00 price objective on shares of Seaport Therapeutics in a research note on Wednesday, July 15th. Five equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Seaport Therapeutics currently has an average rating of "Hold" and an average target price of $38.40. **Read Our Latest Stock Report on Seaport Therapeutics** ## Seaport Therapeutics Stock Up 3.4% The stock's fifty day moving average is $19.60. Seaport Therapeutics (NASDAQ:SPTX - Get Free Report) last announced its earnings results on Monday, August 3rd. The company reported ($1.78) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($1.07). On average, research analysts anticipate that Seaport Therapeutics, Inc. will post -4.33 EPS for the current fiscal year. ## Insiders Place Their Bets In related news, Director Robert J. Hombach acquired 13,000 shares of Seaport Therapeutics stock in a transaction on Monday, June 22nd. The stock was bought at an average cost of $18.14 per share, for a total transaction of $235,820.00. Following the completion of the transaction, the director owned 13,000 shares of the company's stock, valued at approximately $235,820. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. ## Seaport Therapeutics Company Profile (Get Free Report) Seaport Therapeutics Inc is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety and other debilitating neuropsychiatric disorders. Seaport Therapeutics Inc is based in BOSTON. ## Featured Stories - Five stocks we like better than Seaport Therapeutics - Sandisk Just Delivered a Blowout Quarter—Here's Why the Stock Is Falling - 4 Oil and Gas ETF Plays as Prices Stay Sky-High - What Tesla Stands to Lose If It Walks Away From China - Disney Sets Up for a Magical Year in 2027 *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ## Should You Invest $1,000 in Seaport Therapeutics Right Now? Before you consider Seaport Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Seaport Therapeutics wasn't on the list. While Seaport Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [SPTX.US](https://longbridge.com/en/quote/SPTX.US.md) - [SNDK.US](https://longbridge.com/en/quote/SNDK.US.md) - [TSLA.US](https://longbridge.com/en/quote/TSLA.US.md) - [DIS.US](https://longbridge.com/en/quote/DIS.US.md) ## Related News & Research - [Seaport Therapeutics (NASDAQ:SPTX) Now Covered by Analysts at JonesTrading](https://longbridge.com/en/news/297066497.md) - [A $130 Billion Reason to Buy SK Hynix Stock Now](https://longbridge.com/en/news/296820549.md) - [Sterling Infrastructure (NASDAQ:STRL) Trading Up 2.3% - Time to Buy?](https://longbridge.com/en/news/297091941.md) - [Target Is in the Spotlight for All the Right Reasons. Here's Why It's a Buy Now.](https://longbridge.com/en/news/296937826.md) - [SailPoint (NASDAQ:SAIL) Shares Gap Up - Time to Buy?](https://longbridge.com/en/news/297205766.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**